3TC, (−)-2',3'-dideoxy-3'-thiacytidine (common name, lamivudine); ABC, abacavir; ATV, atazanavir; AZT, 3'-azido-3'-deoxy-thymidine (common name, zidovudine); BIC, bictegravir; CAB, cabotegravir; CC50, the 50% cytotoxic concentration; COBI, cobicistat; Clinical efficacy; DOR, doravirine; DPV, dapivirine; DRV, darunavir; DTG, dolutegravir; EACS, European AIDS Clinical Society; EC50, half maximal effective concentration; EFV, efavirenz; ESV, elsulfavirine; EVG, elvitegravir; F, bioavailability; FDA, US Food and Drug Administration; FTC, (−)-2',3'-dideoxy-5-fluoro-3'-thiacytidine (common name, emtricitabine); HAART; HAART, highly active antiretroviral therapy; HIV treatment; HIV, human immunodeficiency virus; IAS-USA, International Antiviral Society-USA; IC50, half maximal inhibitory concentration; MSM, men who have sex with men; NNRTI; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; t1/2, elimination half-life